Evidence map›Paper›PMID 38064031›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Bacterial Artificial Chromosome Reverse Genetics Approaches for SARS-CoV-2.

Kevin Chiem, Aitor Nogales, Fernando Almazán, Chengjin Ye, Luis Martínez-Sobrido

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Kevin ChiemTexas Biomedical Research Institute, San Antonio, TX, USA.
Aitor NogalesCentro de Investigación en Sanidad Animal (CISA-INIA/CSIC), Madrid, Spain.
Fernando AlmazánDepartment of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB), CSIC, Madrid, Spain.
Chengjin YeTexas Biomedical Research Institute, San Antonio, TX, USA. cye@txbiomed.org.
Luis Martínez-SobridoTexas Biomedical Research Institute, San Antonio, TX, USA. lmartinez@txbiomed.org.
Texas Biomedical Research Institute · USCentro Nacional de Biotecnología · ESConsejo Superior de Investigaciones Científicas · ES

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$103.4M
Targeting druggable coronavirus proteinsU19AI171443 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Juan C. de la Torre · 2022 to 2026
$101.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Project 6 - Development of Antivirals against AlphavirusesU19AI171403 · NIAID · EMORY UNIVERSITY · PI George Robert Painter, Richard K. Plemper · 2022 to 2026
$59.7M
Development of a High-Throughput Microfluidics-Enabled Functional Assay for Rapidly Identifying Neutralizing AntibodiesR01AI141607 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI DE FIGUEIREDO, PAUL, HAN, ARUM · 2019 to 2023
$3.4M
Mechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-2R01AI161363 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GUPTA, YOGESH K · 2021 to 2025
$3.2M
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell responseR01AI145332 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2019 to 2022
$3.0M
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus BiologyR01AI142985 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI DE LA TORRE, JUAN C., MARTINEZ-SOBRIDO, LUIS · 2019 to 2022
$1.8M
Developing a Thermostable SARS-CoV-2 RBD-particle VaccineR43AI165089 · NIAID · POP BIOTECHNOLOGIES, INC · PI HUANG, WEI-CHIAO · 2021 to 2022
$600k
NIAID NIH HHS R01 AI141607NIAID NIH HHS R01 AI142985NIAID NIH HHS R01 AI145332NIAID NIH HHS R01 AI161175NIAID NIH HHS R01 AI161363NIAID NIH HHS R43 AI165089NIAID NIH HHS U19 AI171110NIAID NIH HHS U19 AI171403NIAID NIH HHS U19 AI171443NIH HHS 75N93021C00014
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new member of the Coronaviridae family responsible for the coronavirus disease 19 (COVID-19) pandemic. To date, SARS-CoV-2 has been accountable for over 624 million infection cases and more than 6.5 million human deaths. The development and implementation of SARS-CoV-2 reverse genetics approaches have allowed researchers to genetically engineer infectious recombinant (r)SARS-CoV-2 to answer important questions in the biology of SARS-CoV-2 infection. Reverse genetics techniques have also facilitated the generation of rSARS-CoV-2 expressing reporter genes to expedite the identification of compounds with antiviral activity in vivo and in vitro. Likewise, reverse genetics has been used to generate attenuated forms of the virus for their potential implementation as live-attenuated vaccines (LAV) for the prevention of SARS-CoV-2 infection. Here we describe the experimental procedures for the generation of rSARS-CoV-2 using a well-established and robust bacterial artificial chromosome (BAC)-based reverse genetics system. The protocol allows to produce wild-type and mutant rSARS-CoV-2 that can be used to understand the contribution of viral proteins and/or amino acid residues in viral replication and transcription, pathogenesis and transmission, and interaction with cellular host factors.

Indexed as

COVID-19SARS-CoV-2Chromosomes, Artificial, BacterialHumansReverse GeneticsVirus ReplicationBacterial artificial chromosomeCoronavirusCOVID-19Infectious cloneRecombinant virusReverse geneticsSARS-CoV-2

Identifiers

PMID38064031
OpenAlexW4389485698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.